Medgenics to Present Clinical Data at the 20th Congress of the European Hematology Association

Medgenics, Inc. (NYSE MKT: MDGN), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and their own tissue for the treatment of rare and orphan diseases, today announced that clinical data from the ongoing Phase 1/2 study of the Company's TARGTEPOTM (Transduced Autologous Restorative Gene Therapy) system in end stage renal disease will be presented at the 20th Congress of the European Hematology Association (EHA) taking place June 11-14, 2015 in Vienna, Austria. The data will be presented by Dr. Shany Blum, Vice President of Medical Affairs, during a poster session. Details are as follows: Date & Time: Saturday, June 13, 2015 at 5:15 p.m. CEST Title: A Prospective Clinical Trial of Prolonged Autologous Erythropoietin (EPO) Secretion from TARGTEPO In EPO-Dependent End Stage Renal Disease Patients Showed EPO Independence for Over 8 Months Session: Gene Therapy, Cellular Immunotherapy and Vaccination Abstract: P723 Location: Poster area (Hall C) Presentation materials will be available in the Investor Relations portion of the company's website following conclusion of the session. About Medgenics, Inc. Medgenics is developing the TARGT™ (Transduced Autologous Restorative See full press release